Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A, Colleoni M. Viale G, et al. Among authors: bottiglieri l. Breast Cancer Res Treat. 2009 Jul;116(2):317-28. doi: 10.1007/s10549-008-0206-z. Epub 2008 Oct 7. Breast Cancer Res Treat. 2009. PMID: 18839307 Clinical Trial.
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression.
Rocca A, Viale G, Gelber RD, Bottiglieri L, Gelber S, Pruneri G, Ghisini R, Balduzzi A, Pietri E, D'Alessandro C, Goldhirsch A, Colleoni M. Rocca A, et al. Among authors: bottiglieri l. Cancer Chemother Pharmacol. 2008 May;61(6):965-71. doi: 10.1007/s00280-007-0551-3. Epub 2007 Jul 18. Cancer Chemother Pharmacol. 2008. PMID: 17639392
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, Veronesi P, D'Alessandro C, Luini A, Dellapasqua S, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Among authors: bottiglieri l. Br J Cancer. 2007 Sep 17;97(6):802-8. doi: 10.1038/sj.bjc.6603947. Epub 2007 Aug 21. Br J Cancer. 2007. PMID: 17712311 Free PMC article. Clinical Trial.
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.
Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A. Colleoni M, et al. Among authors: bottiglieri l. Ann Oncol. 2008 Mar;19(3):465-72. doi: 10.1093/annonc/mdm509. Epub 2007 Nov 6. Ann Oncol. 2008. PMID: 17986623 Free article.
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Among authors: bottiglieri l. Cancer Chemother Pharmacol. 2008 Sep;62(4):667-72. doi: 10.1007/s00280-007-0652-z. Epub 2007 Dec 7. Cancer Chemother Pharmacol. 2008. PMID: 18064460 Clinical Trial.
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis.
Pruneri G, Alietti A, Agnelli L, Morabito F, Laszlo D, Calabrese L, Fabris S, Bertolini F, Agazzi A, Bottiglieri L, Raviele PR, Baldini L, Pileri S, Sabattini E, Bosari S, Maisonneuve P, Lambertenghi-Deliliers G, Bertoni F, Martinelli G, Viale G, Neri A. Pruneri G, et al. Among authors: bottiglieri l. Leuk Res. 2008 Oct;32(10):1628-32. doi: 10.1016/j.leukres.2008.02.002. Epub 2008 Mar 19. Leuk Res. 2008. PMID: 18355918 No abstract available.
Pathological definition of triple negative breast cancer.
Viale G, Bottiglieri L. Viale G, et al. Among authors: bottiglieri l. Eur J Cancer. 2009 Sep;45 Suppl 1:5-10. doi: 10.1016/S0959-8049(09)70011-5. Eur J Cancer. 2009. PMID: 19775600 No abstract available.
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: bottiglieri l. Breast Cancer Res Treat. 2010 Dec;124(3):689-99. doi: 10.1007/s10549-010-1027-4. Epub 2010 Jul 13. Breast Cancer Res Treat. 2010. PMID: 20625816
Breast cancer subtypes and outcome after local and regional relapse.
Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: bottiglieri l. Ann Oncol. 2012 Feb;23(2):324-31. doi: 10.1093/annonc/mdr129. Epub 2011 Apr 27. Ann Oncol. 2012. PMID: 21525402 Free article.
50 results